摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(1-溴乙基)-5-氟嘧啶 | 188416-47-9

中文名称
4-(1-溴乙基)-5-氟嘧啶
中文别名
4-溴乙基-5-氟嘧啶
英文名称
4-(1-bromoethyl)-5-fluoropyrimidine
英文别名
——
4-(1-溴乙基)-5-氟嘧啶化学式
CAS
188416-47-9
化学式
C6H6BrFN2
mdl
——
分子量
205.029
InChiKey
BXIHJVDQQNZXBD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.616

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090

SDS

SDS:f0faefd7a85c187938c6bf0cd847189d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(1-溴乙基)-5-氟嘧啶lead 、 sodium hydroxide 、 作用下, 以 四氢呋喃甲醇二氯甲烷丙酮 为溶剂, 生成 伏立康唑
    参考文献:
    名称:
    Process Development of Voriconazole:  A Novel Broad-Spectrum Triazole Antifungal Agent
    摘要:
    In the synthesis of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (voriconazole), the relative stereochemistry is set in the addition of a 4-(1-metalloethyl)-5-fluoropyrimidine derivative to 1-(2,4-difluorophenyl)-2-(1H-1 ,2,4-triazol-1-yl)-1-ethanone, The diastereo-control of this reaction has been examined by variation of pyrimidine substitution pattern and by changes in the metalation and reaction conditions. Excellent diastereoselection (12: ii is obtained using an organozinc derivative of 6-(1-bromoethyl)-4-chloro-5-fluoropyriminidine. lifter removal cf the chlorine from the pyrimidine ring? the absolute stereochemistry of voriconazole is established via a diastereomeric salt resolution process using (1R)-10 camphorsulfonic acid. Synthetic routes to the pyrimidine partner have also been evaluated. The initial six-step development route from 5-fluorouracil has been superseded by a four-step synthesis involving fluorination of methyl 3-oxopentanoate and cyclisation with formamidine acetate.
    DOI:
    10.1021/op0000879
  • 作为产物:
    描述:
    2,4-二氯-6-乙基-5-氟嘧啶N-溴代丁二酰亚胺(NBS)偶氮二异丁腈 、 5%-palladium/activated carbon 、 氢气sodium acetate 作用下, 以 甲醇二氯甲烷 为溶剂, 50.0 ℃ 、344.75 kPa 条件下, 反应 11.0h, 生成 4-(1-溴乙基)-5-氟嘧啶
    参考文献:
    名称:
    Process Development of Voriconazole:  A Novel Broad-Spectrum Triazole Antifungal Agent
    摘要:
    In the synthesis of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-triazol-1-yl)-2-butanol (voriconazole), the relative stereochemistry is set in the addition of a 4-(1-metalloethyl)-5-fluoropyrimidine derivative to 1-(2,4-difluorophenyl)-2-(1H-1 ,2,4-triazol-1-yl)-1-ethanone, The diastereo-control of this reaction has been examined by variation of pyrimidine substitution pattern and by changes in the metalation and reaction conditions. Excellent diastereoselection (12: ii is obtained using an organozinc derivative of 6-(1-bromoethyl)-4-chloro-5-fluoropyriminidine. lifter removal cf the chlorine from the pyrimidine ring? the absolute stereochemistry of voriconazole is established via a diastereomeric salt resolution process using (1R)-10 camphorsulfonic acid. Synthetic routes to the pyrimidine partner have also been evaluated. The initial six-step development route from 5-fluorouracil has been superseded by a four-step synthesis involving fluorination of methyl 3-oxopentanoate and cyclisation with formamidine acetate.
    DOI:
    10.1021/op0000879
点击查看最新优质反应信息

文献信息

  • 一种伏立康唑及其中间体的制备方法
    申请人:重庆莱美隆宇药业有限公司
    公开号:CN106117186B
    公开(公告)日:2018-08-24
    本发明提供了一种由伏立康唑异构体制备伏立康唑及其中间体的制备方法。本方法以伏立康唑异构体为原料,于碱性反应条件下,在25~100℃下反应1~24小时,再进行缩合反应,制备获得伏立康唑消旋体,对伏立康唑消旋体进行手性拆分后获得伏立康唑。采用本方法可回收利用工业化生产过程中产生的大量废弃的伏立康唑异构体,避免了制备伏立康唑过程中原辅料及资源的浪费。不仅可以大幅降低生产成本,还可以发展循环生产,起到节约资源及保护环境的目的。
  • [EN] PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR<br/>[FR] PREPARATION DE TRIAZOLES PAR ADDITION DE REACTIFS ORGANOMETALLIQUES A DES CETONES ET INTERMEDIAIRES PREVUS A CET EFFET
    申请人:PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A.
    公开号:WO1997006160A1
    公开(公告)日:1997-02-20
    (EN) The invention provides a process for the preparation of a compound of formula (I), or an acid addition or base salt thereof, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and trifluoromethyl; R1 is C1-C6 alkyl; and 'Het' is pyrimidinyl optionally substituted by 1 to 3 substituents each independently selected from C1-C4 alkyl, C1-C4 alkoxy, halo, oxo, benzyl and benzyloxy, comprising reaction of a compound of formula (II), wherein R is as previously defined for a compound of formula (I), with a compound of formula (III), wherein R1 and 'Het' are as previously defined for a compound of the formula (I) and X is chloro, bromo or iodo, in the presence of zinc, iodine and/or a Lewis acid and an aprotic organic solvent: said process being optionally followed by conversion of the compound of the formula (I) to an acid addition or base salt thereof.(FR) L'invention porte sur un procédé de préparation d'un composé de formule (I), ou d'un sel d'addition d'acide ou de base de celui-ci, où R représente phényle éventuellement substitué par 1 à 3 substituants choisis indépendamment parmi halo et trifluorométhyle; R1 représente alkyle C1-C6; et 'Het' représente pyrimidinyle éventuellement substitué par 1 à 3 substituants choisis indépendamment parmi alkyle C1-C4, alcoxy C1-C4, halo, oxo, benzyle et benzyloxy. Le procédé comprend également la mise en réaction d'un composé de formule (II), où R est comme défini ci-dessus pour un composé de formule (I), avec un composé de formule (III), où R1 et 'Het' sont comme défini ci-dessus pour un composé de formule (I), et X représente chloro, bromo ou iodo, en présence de zinc, d'iode et/ou d'un acide de Lewis et un solvant organique aprotique. Ledit procédé est éventuellement suivi par la conversion du composé de formule (I) en sel d'addition d'acide ou sel de base de celui-ci.
    本发明提供了一种制备公式(I)化合物或其酸加成物或碱盐的过程,其中R是苯基,可选地被1至3个取代基独立地选择自卤素和三氟甲基取代; R1是C1-C6烷基; 'Het'是嘧啶基,可选地被1至3个取代基独立地选择自C1-C4烷基,C1-C4烷氧基,卤素,氧代和苄基和苄氧基,包括将公式(II)化合物与公式(III)化合物反应,其中R如上所述为公式(I)化合物的定义,R1和'Het'如上所述为公式(I)的定义,X是氯,溴或碘,在锌,碘和/或路易斯酸和无水有机溶剂的存在下:该过程可以随后将公式(I)化合物转化为其酸加成物或碱盐。
  • Preparation of triazoles by organometallic addition to ketones and intermediates therefor
    申请人:——
    公开号:US20030181720A1
    公开(公告)日:2003-09-25
    The invention provides a process for the preparation of a compound of the formula: 1 or an acid addition or base salt thereof, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and trifluoromethyl; R 1 is C 1 -C 6 alkyl; and “Het” is pyrimidinyl optionally substituted by 1 to 3 substituents each independently selected from C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo, oxo, benzyl and benzyloxy, comprising reaction of a compound of the formula: 2 wherein R is as previously defined for a compound of the formula (I), with a compound of the formula: 3 wherein R 1 and “Het” are as previously defined for a compound of the formula (I) and X is chloro, bromo or iodo, in the presence of zinc, iodine and/or a Lewis acid and an aprotic organic solvent: said process being optionally followed by conversion of the compound of the formula (I) to an acid addition or base salt thereof.
    本发明提供了一种制备式1化合物或其酸加成物或碱盐的方法,其中R是苯基,可选地被1至3个取代基独立选择的卤素和三氟甲基取代;R1是C1-C6烷基;而“Het”是嘧啶基,可选地被1至3个取代基独立选择的C1-C4烷基,C1-C4烷氧基,卤素,氧代,苄基和苄氧基所取代。该方法包括将式2化合物与式3化合物在锌、碘和/或路易斯酸和无水有机溶剂的存在下反应,其中R1和“Het”与式1化合物中定义的相同,X为氯、溴或碘。该方法可随后将式1化合物转化为其酸加成物或碱盐。
  • 伏立康唑的合成工艺
    申请人:安徽普利药业有限公司
    公开号:CN113354625B
    公开(公告)日:2023-09-26
    本发明公开了伏立康唑原料药的合成工艺,包括以下步骤:准备卤代乙基氟代嘧啶,并进行格氏反应;将2‑(2,4‑二氟苯基)‑3‑(1,2,4‑三唑‑1‑基)‑1,2‑丙二醇进行氧化,得到环氧丙烷化合物;将上述格氏试剂与环氧丙烷化合物混合,进行反应,得到伏立康唑。本发明提供的合成工艺能够简化反应步骤,无需使用钯碳进行脱氯氢解,缩短反应周期,此外,本发明还节约能耗、降低成本,并以较高收率获得伏立康唑及其消旋体。
  • PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR
    申请人:Pfizer Research and Development Company, N.V./S.A.
    公开号:EP0871625B1
    公开(公告)日:2003-12-17
查看更多